Mycophenolate in dermatology

Journal of Dermatological Treatment

Volumn 14, Issue 4, 2003, Pages 203-211

  Liu, V ^a   Mackool, Bonnie T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adverse effects; Dermatologic conditions; MMF; Safety

Indexed keywords

ACICLOVIR; ANTACID AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MAGNESIUM; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROBENECID; SALICYLIC ACID; TACROLIMUS; THALIDOMIDE; TRIAMCINOLONE;

ABDOMINAL CRAMP; ACNE; ALLOGENIC BONE MARROW TRANSPLANTATION; ASPERGILLOSIS; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CONSTIPATION; COUGHING; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DERMATOMYOSITIS; DIARRHEA; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; DYSURIA; ECZEMA; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HEADACHE; HEMANGIOMATOSIS; HEMATURIA; HERPES; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; LEUKOPENIA; LICHEN PLANUS; LIVER TOXICITY; LYMPHOPROLIFERATIVE DISEASE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL EDEMA; POMPHOLYX; PRIORITY JOURNAL; PSORIASIS; PYODERMA GANGRENOSUM; PYURIA; RASH; REVIEW; SARCOIDOSIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; ULTRAVIOLET A RADIATION; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; VASCULITIS; VOMITING;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECZEMA; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LICHEN PLANUS; MALE; MYCOPHENOLIC ACID; PREGNANCY; PSORIASIS; PYODERMA GANGRENOSUM; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SKIN DISEASES; SKIN DISEASES, VESICULOBULLOUS; TREATMENT OUTCOME;

EID: 0344873651     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.1080/09546630310016826     Document Type: Review

References (78)

1. Sulzberger MB, Witten VH, Yaffe S. Cortisone acetate administered orally in dermatologic therapy. Arch Dermatol Syphilol (1951) 64: 573-9.
2. Sulzberger MB, Witten VH. The effect of topically applied Compound F in selected dermatoses. J Invest Dermatol (1952) 19: 101-2.
3. Nesbitt LT Jr. Minimizing complications from systemic glucocorticoid use. Dermatol Clin (1995) 13: 925.
4. Dutz JP, Ho VC. Immunosuppressive agents in dermatology. An update. Dermatol Clin (1998) 16(2): 235-51.
5. Alsberg CL, Black OF. Contribution to the study of maize deterioration. US Dept Agr Plant Industry Bull (1913) 270: 7-48.
6. Abrams R, Bentley M. Biosynthesis of nucleic acid purines. Biochem Biophys (1959) 79: 91-7.
7. Abraham EP. The effect of mycophenolic acid on the growth of staphylococcus aureus in heart broth. Biochem J (1945) 39: 398-404.
8. Cline JC, Nelson JD, Gherzon K et al. In vitro antiviral activity of mycophenolic acid and its reversal by guanine-type compounds. Appl Microbiol (1969) 18: 14-20.
9. Kosugi Y, Saito Y, Mori S et al. Antiviral activities of mizoribine and other inosine monophosphate dehydrogenase inhibitors against several ortho- and paramyxoviruses. Antiviral Chem Chemother (1994) 5: 366-71.
10. Nelson PH, Eugui E, Wang CC, Allison AC. Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid. J Med Chem 33: 833-8.
11. Jones EL, Epinette WW, Hackney VC et al. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol (1975) 65: 537-42.
12. Lee WA. Gu L, Miksztal AR et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res (1990) 7: 161-6.
13. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheum (1993) 11 (suppl 8): S117-119.
14. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet (1995) 345: 1321-5.
15. Sollinger HW. US Renal Transplant Mycophenolate Mofetil Study Group, Mycophenolate mofetil for the prevention of acute rejection in cadaveric renal allograft recipients. Trasnplantation (1995) 60: 225-32.
16. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group, A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation (1996) 61: 1029-1037.
17. Allison AC, Eugui EM. Purine metabolism and the immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant (1996) 10: 77-84.
18. Mehling A, Grabbe S, Voskort M et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol (2000) 165: 2374-81.
19. Physician's Desk Reference. 55th ed. Montvale, NJ: Medical Economics Company: 2001.
20. Nousari HC, Sragovich A, Kimyai-Asadi A et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol (1999) 40: 265-268.
21. Geilen CC, Tebbe B, Garcia Bartels C et al. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol (1999) 141: 175-6.
22. Lynch WS, Roenigk HJ. Mycophenolic acid for psoriasis. Arch Dermatol (1977) 113: 1203-8.
23. Haufs MG, Beissert S, Grabbe S et al. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol (1998) 138: 179-81,
24. Kirby B, Yates VM. Mycophenoate mofetil for psoriasis. Br J Dermatol (1998) 139(2): 357.
25. Tong DW, Walder BK. Widespread plaque psoriasis responsive to mycophenolate mofetil. Australasian J Dennatol (1999) 40(3): 135-7.
26. Grundmann-Kollmann M, Mooser G, Schraeder P et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Derrnatol (2000) 42: 835-7.
27. Davison SC, Morris-Jones R, Powles AV, Fry L. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis. Br J Dermatol (2000) 143: 405-7.
28. Geilen CC, Arnold M, Orfanos CE. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol (2001) 144(3): 583-6.
29. Geilen CC, Mrowietz U. Lack of efficacy of topical mycophenolic acid in psoriasis vulgaris. J Am Acad Dermatol (2000) 42: 837-40.
30. Wohlrab J, Jahn K, Plaetzer M et al. Topical application of mycophenolate mofetil in plaque-type psoriasis, Br J Dermatol (2001) 144(6): 1263-4.
31. Grundmann-Kollmann M, Korting HC, Hehrens S et al. Mychophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol (1999) 40: 957-60.
32. Bredlich RO, Grundmann-Kollmann M, Behrens S et al. Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol (1999) 141: 934.
33. Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol (1999) 135: 54-56.
34. Nousari HC, Griffin WA, Anhalt GJ. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol (1998) 39: 497-8.
35. Bohm M, Beissert S, Schwartz T et al. Bullous pemphigoid treated with mycophenolate mofetil. Lancet (1997) 349: 541-2.
36. Katz KH, Marks JG Jr, Helm KF. Pemphigus foliaceus successfully treated with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol (2000) 42(3): 514-5.
37. Megahed M, Schmiedeberg S, Becker J, Ruzicka T. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol (2001) 45(2): 256-9.
38. Williams JV, Marks JG, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol (2000) 142: 506-8.
39. Hsiao CJ, Hsu M, Lee J et al. Paraneoplastic pemphigus in association with a retroperitoneal Castleman's disease presenting with a lichen planus pemphigoides-like eruption: a case report and review of literature. Br J Dermatol (2001) 144: 372-6.
40. Schattenkirchner S, Eming S, Hunzelmann N et al. Treatment of epidermolysis bullosa acquisita with mycophenolate mofetil and autologous keratinocyte grafting. Br J Dermatol 141: 931-55.
41. Grundmann-Kollmann, Korting HC, Behrens S et al. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol (1999) 141: 154-79.
42. Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil, Br J Dermatol (2000) 143: 385-91.
43. Pickenacker A, Luger TA, Schwarz T. Dyshidrotic eczema treated with mycophenolate mofetil. Arch Derrnatol (1998) 134: 378-9.
44. Nousari HC, Anhalt GJ, Morison WL. Mycophenolate in psoralen-UV-A desensitization therapy for chronic actinic dermatitis. Arch Dermatol (1999) 135: 1128-9.
45. Shoji Y, Fukumura T, Kudo M et al. Effect of topical preparation of mycophenolic acid on experimental allergic contact dermatitis of guinea-pigs induced by dinitrofiuorobenzene. J Pharm Pharmacol (1994) 46(8): 643-6.
46. Nousari HC, Goyal S, Anhalt GJ. Successful treatment of resistant hypertrophic and bullous lichen planus with mycophenolate mofetil. Arch Derrnatol (1999) 135: 1420-1.
47. Nousari HC, Lynch W, Anhalt GJ, Petri M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol (1998) 134: 1509-11.
48. Hohenleutner U, Mohr VD, Michel S, Landthaler M. Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum, Lancet (1997) 350(9093): 1748.
49. Gilmour E, Stewart DG. Severe recalcitrant pyoderma gangrenosusm responding to a combination of mycophenolate mofetil with cyclosporin and complicated by a mononeuritis. Br J Dermatol (2001) 144: 397-400.
50. Wollina U, Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol & Venerol (2000) 14(3): 187-90.
51. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA (2000) 284(12): 1546-8.
52. Fickert P, Hinterleitner TA, Wenzl HH et al. Mycophenolate mofetil in patients with Crohn's disease. Am J Gastroenterol (1998) 93: 2529-32.
53. Altschuler EL. Mycophenolate mofetil. Crohn's disease. measles? Am J Gastroenterol (2000) 95(2): 550-1.
54. Ruiz-Irastorza G, Khamashta MA, Hughes GR. Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin Investig Drugs (2000) 9: 1581-93.
55. Gaubitz M, Schorat A, Schotte H et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus; an open pilot trial. Lupus (1999) 8: 731-6.
56. Schanz S, Ulmer A, Rassner G, Fierlbeck G. Successful treatment of subacute lupus erythematosus with mycophenolate mofetil. Br J Dermatol (2002) 147(1): 174-8.
57. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of four cases. J Rheumatol (2000) 27: 1542-5.
58. Daina E, Schneppati A, Renuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Int Med (1999) 130: 422-6.
59. Nowack R, Birck R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet (1997) 349: 774.
60. Worm M, Sterry W, Olde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaeimic urticarial vasculitis. Br J Dermatol (2000) 143(6): 1324.
61. Nowack R, Gobel U, Klooker P et al. Mycophenolate mofetil for maintenance therapy of Wegeners' granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol (1999) 10(9): 1965-71.
62. Basara N, Kiehl MG, Blau W et al. Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopietic stem cell transplant patients: four years of experience. Transplantation Proceedings (2001) 33(3): 2121-3.
63. Busca A, Saroglia EM, Lanino E et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant (2000) 25: 1067-71.
64. Grundmann-Kollmann M, Behrens S, Gruss C et al. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVAl phototherapy. J Am Acad Dermatol (2000) 42: 134-6.
65. Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol (2003) 148: 147-8.
66. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis: a review of pharmacology. long-term efficacy, and safety. J Am Acad Dermatol (1987) 17: 962-71,
67. US Renal Transplant Mycophenolate Mofetil Study Group, Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis (1999) 34(2): 296-303.
68. Mathew TH. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Transplantation (1998) 65(11): 1450-4.
69. European Mycophenolate Moeftil Cooperative Study Group, Mycophenolate mofetil in renal transplantation: three-year results from the placebo-controlled trial. Transplantation (1999) 68(3): 391-6.
70. Silvermann Kitchin JE, Pomeranz MK, Pak G et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol (1997) 37: 445-9.
71. Jones JW Jr, Ustuner ET, Zdichavsky M et al. Long-term survival of an extremity composite tissue allograft with FK506-mycophenolate mofetil therapy. Surgery (1999) 126: 384-8.
72. Neyts J, DeClercq E. Mycophenolate mofetil strongly potentiates the anti-herpes virus activity of acyclovir. Antiviral Res (1998) 40: 53-6.
73. Sollinger HW, Belzer FO, Deierhoi MH et al. RS-61443 (Mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg (1992) 216: 513-9.
74. Paterson DL, Singh N, Panebianco A et al. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation (1998) 66(5): 593-8.
75. Rostaing L, Izopet J, Sandres K et al. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction on mycophenolate mofetil. Transplantation (2000) 69(5): 991-4.
76. Chapuis AG, Paolo RG, D'Agostino C et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med (2000) 6: 762-8.
77. Ensley RD, Bristow MR, Olsen SL et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation (1993) 56: 75-82.
78. Semhoun-Ducloux S, Ducloux D, Miguet JP. Mycophenophenolate mofetil-induced dyshidrotic eczema. Ann Int Med (2000) 132: 417.